TY - JOUR
T1 - Down syndrome in Africa
T2 - Challenges, opportunities, and future directions
AU - McGlinchey, Eimear
AU - Tewolde, Salina
AU - He, Amanda
AU - Fortea, Juan
AU - Mbakile-Mahlanza, Lingani
AU - Tefera, Ayda
AU - Epenge, Emmanuel
AU - Hassenstab, Jason
AU - Jäck, Alexander
AU - Ranchod, Kirti
AU - El-Jaafary, Shaimaa
AU - Levin, Johannes
AU - Salama, Mohamed
AU - Rubenstein, Eric
AU - Akinyemi, Rufus
AU - Akinyemi, Tolulope
AU - Farombi, Temitope
AU - Lawlor, Brian
AU - Ikanga, Jean
AU - Ashton, Nicholas J.
AU - Stout, Sarah
AU - Balls-Berry, Joyce
AU - Kleinhans, Atholl Valdon
AU - Maina, Rachel
AU - Merali, Zul
N1 - Publisher Copyright:
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2025/6
Y1 - 2025/6
N2 - INTRODUCTION: As life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities. METHODS: This work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care. RESULTS: Limited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. Highlights: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions—such as mobile biomarker sampling and culturally adapted cognitive assessments—offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
AB - INTRODUCTION: As life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities. METHODS: This work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care. RESULTS: Limited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. Highlights: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions—such as mobile biomarker sampling and culturally adapted cognitive assessments—offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
KW - Africa
KW - Alzheimer's disease
KW - Down syndrome
KW - Global South
KW - equity
UR - https://www.scopus.com/pages/publications/105008862653
U2 - 10.1002/alz.70388
DO - 10.1002/alz.70388
M3 - Article
C2 - 40538002
AN - SCOPUS:105008862653
SN - 1552-5260
VL - 21
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 6
M1 - e70388
ER -